Stirling Products to fast-track launch of botanical products in north America

Wednesday, October 14, 2009

Australian listed healthcare company Stirling Products (ASX:STI) has advised that following over six months of research and planning the company is establishing a US network marketing subsidiary to undertake its product launch in North America.

First products to be launched will be ImmunoXel, Cholonorm, Diabetin and Allergon.

The company believes the network marketing approach offers the best leverage for its unique botanical products.

And, provide a rapidly expanding customer base built on referrals without the need to provide for a multi-million
advertising budget, which would otherwise be required for a North American product launch.

Peter Boonen said the company is conservatively targeting having a minimum of 2,500 sales consultants retained within the first six months of operations in North America.

The fast aggregation of a sales force, without the overhead cost building a sales channel - provides scale to marketing the company's products, within a short space of time, which is the benefit of network marketing.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.